Literature DB >> 7738184

Impaired activation of adipocyte lipolysis in familial combined hyperlipidemia.

S Reynisdottir1, M Eriksson, B Angelin, P Arner.   

Abstract

The pathophysiology of familial combined hyperlipidemia (FCHL) is unknown, but altered lipid turnover in peripheral tissues as well as hepatic overproduction of apolipoprotein B have been suggested as possible causes. In the present study, we explored whether a change in triglyceride breakdown by lipolysis in fat cells is present in FCHL. Lipolysis activation by catecholamines was examined in isolated subcutaneous adipocytes from 10 patients with FCHL and 22 healthy control subjects. Lipolysis rate was linear for at least 3 h in both groups. However, a marked (approximately 65%) decrease in the lipolytic response to noradrenaline was found in FCHL. This was also true when lipolysis was maximally stimulated at the receptor level with isoprenaline (nonselective beta-adrenergic agonist), at the adenylyl cyclase level with forskolin, or at the level of the protein kinase hormone-sensitive lipase complex with dibutyryl cAMP. The maximum enzymatic activity of hormone-sensitive lipase was decreased by approximately 40% in FCHL. On the other hand, the lipolytic sensitivity of alpha 2-, beta 1-, and beta 2-adrenoceptors was normal in this condition, as was the number and affinity of beta 1- and beta 2-adrenoceptors. Variations in the maximum lipolysis rate correlated significantly with the variations in hormone-sensitive lipase activity in the whole material, and with the serum values for triglycerides, HDL cholesterol and apoB lipoprotein within the control group, but the serum triglyceride values in FCHL were higher than this correlation predicted. In conclusion, the data demonstrate a marked resistance to the lipolytic effect of catecholamines in fat cells from patients with FCHL, in spite of normal adrenoceptor function. The lipolytic defect appears predominantly to be due to a defect in hormone-sensitive lipase, and may be of importance in the pathophysiology of FCHL.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7738184      PMCID: PMC295819          DOI: 10.1172/JCI117905

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  34 in total

1.  METABOLISM OF ISOLATED FAT CELLS. I. EFFECTS OF HORMONES ON GLUCOSE METABOLISM AND LIPOLYSIS.

Authors:  M RODBELL
Journal:  J Biol Chem       Date:  1964-02       Impact factor: 5.157

2.  Inheritance of combined hyperlipoproteinemia: evidence for a new lipoprotein phenotype.

Authors:  H G Rose; P Kranz; M Weinstock; J Juliano; J I Haft
Journal:  Am J Med       Date:  1973-02       Impact factor: 4.965

3.  Family study of serum lipids and lipoproteins in coronary heart-disease.

Authors:  E A Nikkilä; A Aro
Journal:  Lancet       Date:  1973-05-05       Impact factor: 79.321

4.  Hormone-sensitive lipase: quantitation of enzyme activity and mRNA level in small biopsies of human adipose tissue.

Authors:  K N Frayn; D Langin; C Holm; P Belfrage
Journal:  Clin Chim Acta       Date:  1993-07-16       Impact factor: 3.786

Review 5.  Fat cell adrenergic receptors and the control of white and brown fat cell function.

Authors:  M Lafontan; M Berlan
Journal:  J Lipid Res       Date:  1993-07       Impact factor: 5.922

6.  Simvastatin improves chylomicron remnant removal in familial combined hyperlipidemia without changing chylomicron conversion.

Authors:  M C Cabezas; T W de Bruin; L A Kock; W Kortlandt; M Van Linde-Sibenius Trip; H Jansen; D W Erkelens
Journal:  Metabolism       Date:  1993-04       Impact factor: 8.694

7.  Impaired fatty acid metabolism in familial combined hyperlipidemia. A mechanism associating hepatic apolipoprotein B overproduction and insulin resistance.

Authors:  M Castro Cabezas; T W de Bruin; H W de Valk; C C Shoulders; H Jansen; D Willem Erkelens
Journal:  J Clin Invest       Date:  1993-07       Impact factor: 14.808

8.  Lipolytic catecholamine resistance due to decreased beta 2-adrenoceptor expression in fat cells.

Authors:  F Lönnqvist; H Wahrenberg; L Hellström; S Reynisdottir; P Arner
Journal:  J Clin Invest       Date:  1992-12       Impact factor: 14.808

9.  The adipsin-acylation stimulating protein system and regulation of intracellular triglyceride synthesis.

Authors:  A Baldo; A D Sniderman; S St-Luce; R K Avramoglu; M Maslowska; B Hoang; J C Monge; A Bell; S Mulay; K Cianflone
Journal:  J Clin Invest       Date:  1993-09       Impact factor: 14.808

10.  Methods for the determination of adipose cell size in man and animals.

Authors:  J Hirsch; E Gallian
Journal:  J Lipid Res       Date:  1968-01       Impact factor: 5.922

View more
  24 in total

Review 1.  Monogenic dyslipidemias: window on determinants of plasma lipoprotein metabolism.

Authors:  R A Hegele
Journal:  Am J Hum Genet       Date:  2001-10-26       Impact factor: 11.025

Review 2.  Metabolic pathogenesis of familial combined hyperlipidaemia with emphasis on insulin resistance, adipose tissue metabolism and free fatty acids.

Authors:  Jacqueline de Graaf; Mario J Veerkamp; Anton F H Stalenhoef
Journal:  J R Soc Med       Date:  2002       Impact factor: 5.344

Review 3.  The genetics of familial combined hyperlipidaemia.

Authors:  Martijn C G J Brouwers; Marleen M J van Greevenbroek; Coen D A Stehouwer; Jacqueline de Graaf; Anton F H Stalenhoef
Journal:  Nat Rev Endocrinol       Date:  2012-02-14       Impact factor: 43.330

4.  Combined hyperlipidemia in transgenic mice overexpressing human apolipoprotein Cl.

Authors:  N S Shachter; T Ebara; R Ramakrishnan; G Steiner; J L Breslow; H N Ginsberg; J D Smith
Journal:  J Clin Invest       Date:  1996-08-01       Impact factor: 14.808

5.  Genomewide scan for familial combined hyperlipidemia genes in finnish families, suggesting multiple susceptibility loci influencing triglyceride, cholesterol, and apolipoprotein B levels.

Authors:  P Pajukanta; J D Terwilliger; M Perola; T Hiekkalinna; I Nuotio; P Ellonen; M Parkkonen; J Hartiala; K Ylitalo; J Pihlajamäki; K Porkka; M Laakso; J Viikari; C Ehnholm; M R Taskinen; L Peltonen
Journal:  Am J Hum Genet       Date:  1999-05       Impact factor: 11.025

6.  alpha2-Heremans-Schmid glycoprotein gene polymorphisms are associated with adipocyte insulin action.

Authors:  I Dahlman; P Eriksson; M Kaaman; H Jiao; C M Lindgren; J Kere; P Arner
Journal:  Diabetologia       Date:  2004-12-01       Impact factor: 10.122

7.  Dynamics of human adipose lipid turnover in health and metabolic disease.

Authors:  Peter Arner; Samuel Bernard; Mehran Salehpour; Göran Possnert; Jakob Liebl; Peter Steier; Bruce A Buchholz; Mats Eriksson; Erik Arner; Hans Hauner; Thomas Skurk; Mikael Rydén; Keith N Frayn; Kirsty L Spalding
Journal:  Nature       Date:  2011-09-25       Impact factor: 49.962

8.  Upstream transcription factor 1 gene polymorphisms are associated with high antilipolytic insulin sensitivity and show gene-gene interactions.

Authors:  Konstantinos Kantartzis; Andreas Fritsche; Fausto Machicao; Michael Stumvoll; Jürgen Machann; Fritz Schick; Hans-Ulrich Häring; Norbert Stefan
Journal:  J Mol Med (Berl)       Date:  2006-09-26       Impact factor: 4.599

9.  Adipocyte lipolysis in normal weight subjects with obesity among first-degree relatives.

Authors:  L Hellström; D Langin; S Reynisdottir; M Dauzats; P Arner
Journal:  Diabetologia       Date:  1996-08       Impact factor: 10.122

10.  Sterol-mediated regulation of hormone-sensitive lipase in 3T3-L1 adipocytes.

Authors:  Shinji Miura; Hiromi Nagura; Fusae Sawamura; Isao Tomita; Eiji Kawai; Norihiro Mochizuki; Masahiko Ikeda; Fredric B Kraemer; Takako Tomita
Journal:  Lipids       Date:  2003-07       Impact factor: 1.880

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.